Assignee
SANTARIS PHARMA AS
13 granted patents·18 pending applications·1,207 citations·filing 2001–2015
Top patents by PatentIndex Score
31 records- 0198US7589190B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionSANTARIS PHARMA AS·Filed 2005·Granted Sep 15, 2009·129 cites·8 claims
- 0297US9428534B2Antisense designSANTARIS PHARMA AS·Filed 2013·Granted Aug 30, 2016·46 cites·78 claims
- 0397US7687617B2Oligonucleotides with alternating segments of locked and non-locked nucleotidesSANTARIS PHARMA AS·Filed 2003·Granted Mar 30, 2010·207 cites·26 claims
- 0496US7569575B2Synthesis of locked nucleic acid derivativesSANTARIS PHARMA AS·Filed 2003·Granted Aug 4, 2009·282 cites·8 claims
- 0594US7622453B2Oligomeric compounds for the modulation of Bcl-2SANTARIS PHARMA AS·Filed 2004·Granted Nov 24, 2009·114 cites·57 claims
- 0692US6998484B2Synthesis of purine locked nucleic acid analoguesSANTARIS PHARMA AS·Filed 2001·Granted Feb 14, 2006·259 cites·51 claims
- 0791US8361980B2Pharmaceutical compositions for treatment of microRNA related diseasesSANTARIS PHARMA AS·Filed 2009·Granted Jan 29, 2013·40 cites·31 claims
- 0891US7153954B2Method for preparation of LNA phosphoramiditesSANTARIS PHARMA AS·Filed 2002·Granted Dec 26, 2006·111 cites·7 claims
- 0987US8026355B2Oligomeric compounds for the modulation of survivin expressionSANTARIS PHARMA AS·Filed 2010·Granted Sep 27, 2011·10 cites·9 claims
- 1082US9133455B2Pharmaceutical composition comprising anti-miRNA antisense oligonucleotidesSANTARIS PHARMA AS·Filed 2014·Granted Sep 15, 2015·4 cites·21 claims
- 1175US9447138B2Potent LNA oligonucleotides for the inhibition of HIF-1a expressionSANTARIS PHARMA AS·Filed 2013·Granted Sep 20, 2016·1 cites·4 claims
- 1275US9297010B2Short interfering RNA (siRNA) analoguesSANTARIS PHARMA AS·Filed 2014·Granted Mar 29, 2016·2 cites·30 claims
- 1370US2014128591A1Antisense designSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1468US6858726B2Synthesis of allofuranoseSANTARIS PHARMA AS·Filed 2002·Granted Feb 22, 2005·2 cites·16 claims
- 1568US2014194614A1Amino-lna, thio-lna and alpha-l-oxy-lnSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1666US2014128586A1Amino-lna, thio-lna and alpha-l-oxy-lnSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1764US2009005335A1Compounds for the modulation of beta-catenin expressionSANTARIS PHARMA AS·Filed 2008·Application pending·0 cites
- 1862US2009264353A1Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of DiseaseSANTARIS PHARMA AS·Filed 2007·Application pending·0 cites
- 1961US2010004320A1Pharmaceutical CompositionSANTARIS PHARMA AS·Filed 2007·Application pending·0 cites
- 2059US2014357849A1Splice switching oligomers for tnf superfamily receptors and their use in treatment of diseaseSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2158US2014031409A1Methods for treating androgen receptor dependent disorders including cancersSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2250US2006154888A1LNA oligonucleotides and the treatment of cancerSANTARIS PHARMA AS·Filed 2005·Application pending·0 cites
- 2349US2004248840A1Oligomeric compounds for the modulation of ras expressionSANTARIS PHARMA AS·Filed 2004·Application pending·0 cites
- 2449US2010323967A1RNA Antagonist Compounds for the Modulation of MCL-1SANTARIS PHARMA AS·Filed 2008·Application pending·0 cites
- 2546US2004241717A1Oligomeric compounds for the modulation of thioredoxin expressionSANTARIS PHARMA AS·Filed 2004·Application pending·0 cites
- 2643US2014343127A1Compounds for the modulation of smn2 splicingSANTARIS PHARMA AS·Filed 2012·Application pending·0 cites
- 2742US2010062994A1Adenosine Receptor AntagonistsSANTARIS PHARMA AS·Filed 2007·Application pending·0 cites
- 2842US2015315595A1Compositions and Methods for Modulation of ATXN3 ExpressionSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2942US2008249039A1Modified Short Interfering Rna (Modified Sirna)SANTARIS PHARMA AS·Filed 2005·Application pending·0 cites
- 3040US2014323557A1Compounds for the modulation of beta-catenin expression and uses thereofSANTARIS PHARMA AS·Filed 2012·Application pending·0 cites
- 3138US2015252371A1Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of DiseaseSANTARIS PHARMA AS·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →